Obesity Pillars

Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials

By Deborah Bade Horn, Alpana P. Shukla, Haocheng Huang, Sanja Giljanovic Kiš

Randomised trial in 616 peopleInterventions

72 weeks, double-blind, placebo-controlled, registered NCT05869903

The paper

Deborah Bade Horn, Alpana P. Shukla, Haocheng Huang, Sanja Giljanovic Kiš

University of Texas McGovern Medical School; Eli Lilly (United States)

Obesity Pillars, 14 Jul 2026

doi.org/10.1016/j.obpill.2026.100301 PubMed 42577069

Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity